Brainstorm Cell Therapeutics Discounted Cash Flow

Brainstorm Cell Therapeutics's discounted cash flow stands at $-0.019. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Discounted cash flow values BCLI by forecasting cash the business could generate and bringing those cash flows to present value. Stockcircle's latest estimate is $-0.019, implying the shares look overvalued by about 102.2%. Pair DCF with P/E, growth, and balance-sheet metrics before making a decision.

The history chart shows how Brainstorm Cell Therapeutics's DCF fair value evolved across reporting periods, while the comparison chart places BCLI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, DCF fair value is commonly used to spot outliers. Brainstorm Cell Therapeutics's reading of $-0.019 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.